Redesigning paclitaxel: expanding the therapeutic window through oral delivery

By Drug Target Review2025-12-01T09:00:03

The potent chemotherapy drug paclitaxel is widely employed for various cancers despite toxicity and efficacy challenges. Maite Agüeros reveals how novel nanoparticle technology has enabled oral delivery of the drug – showing promising signs of improved tolerability and treatment success.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member